Translational Immuno-Oncology

My group`s cancer research is focussed on immunotherapy of solid tumors as well as the biology and targeting of lymphoma. In all our cancer projects we strive to gain a better understanding of resistance to systemic treatment and its prevention and monitoring. The strength of our research consists in its translational character. Clinical trials are therefore one major focus of our work.

Selected Publications

Märkl, Florian, Schultheiß, Christoph, Ali, Murtaza, Chen, Shih-Shih, Zintchenko, Marina, Egli, Lukas, Mietz, Juliane, Chijioke, Obinna, Paschold, Lisa, Spajic, Sebastijan, Holtermann, Anne, Dörr, Janina, Stock, Sophia, Zingg, Andreas, Läubli, Heinz, Piseddu, Ignazio, Anz, David, Minden, Marcus Dühren-von, Zhang, Tianjiao, et al. (2024). Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature Communications, 15. https://doi.org/10.1038/s41467-024-45378-w

URLs

Paschold, L., Willscher, E., Bein, J., Vornanen, M., Eichenauer, D. A., Simnica, D., Thiele, B., Wickenhauser, C., Rosenwald, A., Bernd, H.-W., Klapper, W., Feller, A. C., Ott, G., Fend, F., Hartmann, S., & Binder, M. (2021). Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica, 106(10), 2654–2666. https://doi.org/10.3324/haematol.2021.278427

URLs

Prof. Dr. med. Mascha Binder

Translational Immuno-Oncology

Selected Publications